Scott Tagawa, MD, MS, FACP

GU Oncology Now

<p>Scott Tagawa, MD, MS, FACP, Professor of Medicine and Urology at Weill Cornell Medicine, and an Attending Physician at New York-Presbyterian &ndash; Weill Cornell Medical Center, shares what needs to happen for radionuclide therapies to make their way into the community setting. How can community oncologists and urologists prepare themselves to offer these therapies?<p>View Dr. Tagawa&rsquo;s other comments on prostate cancer management, including <a href="https://guoncologynow.com/post/psma-pet-versus-cross-sectional-imaging" target="_blank" rel="noopener">PSMA PET Versus Cross-Sectional Imaging</a> and <a href="https://guoncologynow.com/post/lutetium-177-psma-617-appropriate-and-potential-off-label-utility" target="_blank" rel="noopener">Appropriate and Potential Off-Label Utility of Lutetium-177&ndash;PSMA-617</a>.</p></p>


RLT Administration in the Community Setting

Radioligand therapy prostate-specific membrane antigen

Scott Tagawa, MD, MS, FACP, shares what needs to happen for radionuclide therapies to make their way into the community setting.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe